MicroRNA-18a-3p as a biomarker for neonatal respiratory distress syndrome and its effects in alveolar epithelial type II cells Authors: Yujie Shi, Ye Jin, Hui Yu Published: 2026 ABSTRACT AbstractBackgroundNeonatal respiratory distress syndrome (NRDS) is a major cause of significant morbidity and mortality among neonates, particularly in preterm infants. Existing studies have highlighted various microRNAs (miRNAs) implicated in NRDS, yet the precise molecular mechanisms, particularly regarding miR-18a-3p, remain incompletely understood. This research aimed to elucidate the role of miR-18a-3p as a potential biomarker for NRDS and to explore its functional mechanisms in alveolar type II epithelial cells.MethodA total of 35 NRDS patients and 35 healthy controls were enrolled, with samples of amniotic fluid and neonatal blood collected for expression analysis of miR-18a-3p. Utilizing cell culture, transfection, qRT-PCR techniques, CCK-8 assay, and ELISA assay, the function of miR-18a-3p in alveolar epithelial type II cells (an immortalized cell line, IHPEC-II, and AEC2-like cells derived from human pluripotent stem cells) was investigated. The binding relationship between miR-18a-3p and surfactant pulmonary-associated protein C (SFTPC) was predicted and validated using a dual-luciferase reporter assay.ResultsElevated levels of miR-18a-3p levels were observed in the serum of NRDS cases, with an area under the ROC curve (AUC) of 0.86 for distinguishing NRDS from healthy controls. Increased miR-18a-3p levels were also detected in amniotic fluid from these NRDS cases, yielding an ROC AUC of 0.82 for discriminating between NRDS cases and healthy controls. A positive correlation between serum miR-18a-3p levels and those in amniotic fluid was observed. Functional assays demonstrated that inhibition of miR-18a-3p significantly enhanced cell viability and increased SPC secretion in alveolar epithelial type II cells following surfactant stimulation. Dual-luciferase reporter assays confirmed that miR-18a-3p modulated SFTPC expression.ConclusionMiR-18a-3p was increased in NRDS cases. MiR-18a-3p can inhibit alveolar epithelial type II cell function, suggesting its potential role in fetal lung development.Keywords: MiR-18a-3p, neonatal respiratory distress syndrome, alveolar epithelial cells, SFTPC Background Neonatal respiratory distress syndrome (NRDS) represents a significant clinical challenge in neonatal medicine, often leading to substantial morbidity and mortality among affected infants [1]. NRDS is a common condition affecting neonates, characterized by compromised respiratory function [2]. The main cause of NRDS varies depending on the gestational age [3]. Due to the lungs’ structural and functional immaturity, pulmonary surfactant deficiency is the most common cause of preterm infants [4]. In term infants, NRDS is uncommon and often secondary to genetic surfactant dysfunction or perinatal stress, while transient tachycardia neonatal (TTN) is a different clinical entity [5]. The pathophysiology of NRDS is intricately linked to several risk factors, including gestational age, birth weight, and mode of delivery [6]. The development of surfactant-producing type II alveolar cells is crucial for lung maturity, and any disruption in this process can result in inadequate surfactant levels, precipitating NRDS [7–9]. Clinical presentation usually includes tachypnea, wheezing, nasal flushing, withdrawal, and hypoxemia, which are not specific but require immediate evaluation. Currently, the diagnosis of NRDS requires a comprehensive assessment integrating risk factors, clinical signs, imaging, and laboratory data, as the syndrome lacks a single definitive criterion [10]. Evaluation begins with a review of the perinatal history to identify predisposing conditions. Type II alveolar cells perform several principal functions, including surfactant production and secretion, transepithelial regulation of water and ion flux, expression of immunomodulatory proteins, and regeneration of the alveolar epithelium following injury [11, 12]. Finding molecular regulators of AT2 cell function, such as microRNAs, is crucial for creating new biomarkers and therapeutic targets for NRDS because of the critical role that AT2 cells play in surfactant production and lung regeneration. Existing literature highlights the role of various biomarkers and molecular pathways involved in the pathogenesis of NRDS [13, 14]. Recent studies have identified microRNAs (miRNAs or miR) as pivotal regulatory molecules in this context, influencing cellular processes such as proliferation, differentiation, and apoptosis within the pulmonary environment [15, 16]. Specifically, alterations in the expression of miRNAs, including those involved in surfactant synthesis and lung development, have been observed in the context of NRDS [17, 18]. Serum miR-92 and miR-122 have been identified to be highly expressed in NRDS, and have the potential to predict the prognosis of NRDS [17]. Umbilical cord serum miR-375 is elevated in NRDS cases and can serve as a biomarker for the diagnosis and prognosis of NRDS [19]. MiR-18a-3p can inhibit inflammation in osteoarthritis by suppressing PDP1 [20]. The role of miR-18a-3p in NRDS pathophysiology, specifically in AT2 cell function, has not been investigated, despite the fact that it has been linked to pulmonary inflammation through H19 regulation [21]. To address these gaps, this study enrolled NRDS patients, as well as healthy controls, to analyze the expression of miR-18a-3p in amniotic fluid and neonatal blood samples from both groups. By integrating methods including cell culture, transfection, and quantitative real-time PCR (qRT-PCR), this research aims to elucidate the clinical relevance of miR-18a-3p in NRDS and the functional role of this molecule within type II alveolar cells. Furthermore, by predicting and validating the targets of miR-18a-3p, this study explored its underlying mechanisms. Methods Study population This study was approved by the Institutional Review Board of Nantong First People’s Hospital. Written informed consent was obtained from all parents or guardians. Sample size was calculated by PASS software, using the ‘Confidence Intervals for the Area Under an ROC Curve’ method with a confidence level of 1-alpha = 0.9. Finally, thirty-five neonates diagnosed with NRDS within the first 24 h of life and thirty-five gestational age-matched healthy controls were enrolled between January 2022 and December 2024. For the NRDS group, the inclusion criteria were: [1] diagnosis of NRDS based on clinical signs (tachypnea, retractions, wheezing), need for respiratory support, and chest radiographic findings; and [2] availability of serum and amniotic fluid samples. Exclusion criteria included chromosomal abnormalities, major congenital anomalies, sepsis, or meconium aspiration syndrome. Peripheral venous blood (2 mL) was drawn from all neonates within 6 h of birth. Residual amniotic fluid samples, originally collected via amniocentesis for clinical indications before delivery were also obtained. All samples were processed within 2 h. Serum was separated by centrifugation and stored at -80 °C. Cell culture and differentiation Human pluripotent stem cells (hPSCs) were obtained from CellAPY Company (CA4002106, Beijing, China) and maintained in mTeSR1 medium (STEMCELL, Canada). Differentiation into alveolar epithelial type II-like cells (AEC2-like cells) was performed using a previously published, modified protocol [22]. Briefly, definitive endoderm induction was followed by anterior foregut endoderm specification and subsequent differentiation into NKX2-1+ lung progenitor cells. These progenitors were then cultured in a cocktail containing CHIR99021 (Tocris Bioscience, UK), dexamethasone (Sigma, Taufkirchen, Germany), 0.1 mM 8-Bromoadenosine 3’,5’-cyclic monophosphate sodium salt (Sigma, Germany), and 0.1 mM 3-Isobutyl-1-methylxanthine (IBMX; Sigma, Germany) for 14 days to generate AEC2-like cells. The immortalized human pulmonary epithelial cell line IHPEC-II (obtained from China Center for Type Culture Collection) was cultured in Minimum Essential Medium with Earle’s Balanced Salts (MEM-EBSS; Hyclone, USA) supplemented with 10% FBS. All cells were maintained at 37 °C in a 5% CO₂ incubator. Cell transfection For functional studies, hPSC-derived AEC2-like cells or IHPEC-II cells at passage 3–5 were used. Cells were transfected with 50 nM miR-18a-3p inhibitor (anti18a-3p) or negative control inhibitor (antiNC) (both from RiboBio, China) using Lipofectamine 3000 (Invitrogen, USA) for 48 h. RNA extraction and qRT-PCR Total RNA was extracted from serum and amniotic fluid using the miRNeasy Serum/Plasma Kit (Qiagen, Germany) following the manufacturer’s protocol. For cell samples, RNA was extracted using the standard RNA Trizol (Invitrogen, USA) extraction method. Reverse transcription was performed using the miScript II RT Kit (Qiagen, Germany) or the Super ScriptTM III Reverse Transcriptase Kit (Invitrogen, Thermo Fisher Scientific, USA). The expression level of miR-18a-3p was quantified by qRT-PCR on a QuantStudio 5 Real-Time PCR System (Applied Biosystems, USA) with the miScript SYBR Green PCR Kit (Qiagen, Germany) or SYBR Green PCR Master Mix (Applied Biosystems, USA). The small nuclear RNA U6 (RNU6B) served as the endogenous control for miR-18a-3p, while GAPDH served as the control for surfactant pulmonary-associated protein C (SFTPC) mRNA. The relative miRNA/mRNA expression was calculated using the comparative 2-ΔΔCt method. Assessment of cell viability CCK-8 assay was applied to both IHPEC-II cells and freshly AEC2-like cells from hPSCs. Briefly, cells were seeded in 96-well plates at a density of 2 × 103 cells per well. After 72 h of culture, CCK-8 reagent was added to each well, followed by incubation and detection at 450 nm using a Spark microplate reader (Tecan Japan, Japan). ELISA for surfactant protein C (SPC) secretion For the analysis of SPC secretion, cell culture supernatants were collected from transfected hPSC-derived AEC2 cells (hPSCs-AEC2) and IHPEC-II cells before and after stimulation. SPC levels were quantified using a commercial ELISA kit following the provided protocol. Briefly, cells were seeded in 96-well plates and allowed to adhere overnight. Following two washes with phosphate-buffered saline, the medium was replaced. After a 30-minute incubation at 37 °C, the supernatant was collected. The remaining cells were then stimulated for 2 h at 37 °C with a cocktail of known surfactant secretagogues (100 µM ATP, 0.1 µM PMA, and 10 µM terbutaline). Parallel, unstimulated cultures served as negative controls. Dual-Luciferase reporter assay The wild-type (WT) 3’-untranslated region (3’-UTR) of the human SFTPC gene containing the predicted miR-18a-3p binding site was subcloned into the pmirGLO dual-luciferase vector (Promega, USA). A mutant (MUT) construct with a 7-base pair mutation in the seed region was generated using site-directed mutagenesis. Cells were co-transfected with either the WT-(or MUT-) SFTPC reporter plasmid alongside the miR-18a-3p inhibitor or the antiNC. Luciferase activities were measured using the Dual-Luciferase Reporter Assay System (Promega). The Firefly/Renilla luciferase activity ratio was calculated and normalized to the control. Statistical analysis Continuous variables were presented as mean ± standard deviation (SD). Differences (p-value < 0.05) among groups were analyzed using Student’s t-test or ANOVA tests. Categorical variables were compared using the Chi-square test (p-value < 0.05). Correlation analysis was performed using Pearson’s correlation coefficient. The diagnostic performance of miR-18a-3p was evaluated by receiver operating characteristic (ROC) curve analysis. Results Clinical characteristics of the study cohort Table 1 presents the baseline demographic and clinical characteristics of the study participants, which included 35 neonates with NRDS and 35 healthy controls. The two groups were matched, with no statistically significant differences in gender, mode of delivery, gestational age, or birth weight (all p > 0.05). As expected, the NRDS group exhibited significantly lower Apgar scores at 1 and 5 min, along with elevated heart and respiratory rates and O2 saturation (all p < 0.001). Table 1Clinical basic characteristicsHealthy controls (n = 35)NRDS (n = 35)p valueGender (Female/Male)18/1717/180.811Delivery mode (vaginal/cesarean)13/2214/210.806Gestational age (weeks)32.74 ± 2.5733.11 ± 2.420.5361-minute Apgar Score8.57 ± 1.048.26 ± 1.09< 0.0015-minute Apgar Score8.66 ± 0.807.46 ± 1.07< 0.001Birth weight (g)1994.34 ± 264.401877.93 ± 215.990.061Heart rate (beat/minute)116.09 ± 2.96128.17 ± 6.56< 0.001Respiratory rate (breath/minute)36.94 ± 1.4180.46 ± 5.47< 0.001O2 saturation98.48 ± 0.5182.66 ± 3.23< 0.001Serum miR-18a-3p1.00 ± 0.621.85 ± 0.48< 0.001Amniotic fluid miR-18a-3p1.00 ± 0.521.66 ± 0.52< 0.001NRDS neonatal respiratory distress syndrome Clinical basic characteristics NRDS neonatal respiratory distress syndrome Elevated circulating miR-18a-3p had diagnostic potential for NRDS We first measured serum miR-18a-3p levels in all neonates. The expression of miR-18a-3p was significantly higher in the NRDS group compared to healthy controls (Table 1; Fig. 1A). To evaluate its diagnostic potential, we performed ROC curve analysis. Serum miR-18a-3p yielded an area under the curve (AUC) of 0.86 (95% CI: 0.78–0.95), with a sensitivity of 77.1% and a specificity of 88.6% at the optimal cut-off value (1.59) (Fig. 1B). MiR-18a-3p in NRDS serum. A The expression level of miR-18a-3p is elevated in the serum of NRDS neonates. B miR-18a-3p in the serum of neonates can distinguish NRDS from healthy subjects. The AUC of ROC was 0.86 Amniotic fluid miR-18a-3p is correlated with serum levels and shows diagnostic value We next analyzed the matched amniotic fluid samples from the NRDS group and controls. Consistently, amniotic fluid miR-18a-3p levels were higher in the NRDS group, when compared to those in control amniotic fluid from non-NRDS pregnancies (Fig. 2A). A significant positive correlation was found between miR-18a-3p expression in paired amniotic fluid and serum samples from NRDS neonates (r = 0.60, p = 0.0002) (Fig. 2B). Furthermore, amniotic fluid miR-18a-3p demonstrated a diagnostic capability for NRDS, with an AUC of 0.82 (95% CI: 0.72–0.92) (Fig. 2C). MiR-18a-3p in NRDS amniotic fluid. A The expression level of miR-18a-3p is elevated in amniotic fluid (AF); B The expression level of miR-18a-3p in amniotic fluid was positively correlated with the expression level of miR-18a-3p in the serum of neonates; C miR-18a-3p in amniotic fluid can distinguish NRDS from healthy subjects. The AUC of ROC was 0.82 Inhibition of miR-18a-3p enhances proliferation and surfactant secretion in alveolar epithelial type II cells To investigate the functional role of miR-18a-3p in alveolar type II cells, we employed in vitro experiments. In IHPEC-II cells, miR-18a-3p showed lower expression levels compared with hPSCs (Fig. 3A). Following differentiation of hPSCs into AEC2-like cells, miR-18a-3p expression was found significantly downregulated compared to undifferentiated hPSCs (Fig. 3B). We then inhibited miR-18a-3p in hPSC-derived AEC2-like cells. CCK-8 assays revealed that inhibition of miR-18a-3p (hPSCs-AEC2-anti18a-3p) significantly enhanced cell viability compared to the negative control (hPSCs-AEC2-antiNC), although the effect remained lower than that observed in the positive control IHPEC-II cell line (Fig. 3C). Importantly, upon stimulation with surfactant secretagogues (ATP, PMA, and terbutaline), SPC secretion was significantly increased in hPSCs-AEC2-anti18a-3p cells relative to the negative control cells (Fig. 3D). Inhibition of miR-18a-3p promoted alveolar epithelial type II viability and secretion of surfactant protein C (SPC). A Compared to human pluripotent stem cells (hPSCs), the expression level of miR-18a-3p was lower in IHPEC-Ⅱ cells; B Compared to hPSCs, the expression level of miR-18a-3p was reduced in AEC2-like cells; C CCK-8 assay of the immortalized human alveolar type II epithelial cell line IHPEC-Ⅱ and AEC2-like cells after transfection. D After stimulation with pulmonary surfactant secretagogues (ATP, PMA, and Terbutaline), the secretion of SPC in hPSCs-AEC2-anti18a-3p cells significantly increased compared to hPSCs-AEC2-antiNC. The immortalized human alveolar type II epithelial cell line IHPEC-Ⅱ was used as a positive control miR-18a-3p targets SFTPC and regulates its expression Bioinformatics analysis predicted a binding site for miR-18a-3p within the 3’-UTR of the SFTPC gene (Fig. 4A). Dual-luciferase reporter assays confirmed this interaction. Co-transfection of the miR-18a-3p inhibitor with the WT-SFTPC 3’-UTR reporter led to a significant increase in luciferase activity, whereas it did not affect the MUT reporter construct (Fig. 4B, C). Subsequently, we measured SFTPC mRNA levels in established IHPEC-II and AEC2-like cells relative to hPSCs. Notably, SFTPC mRNA expression was significantly higher in IHPEC-II (Fig. 4D) and AEC2-like cells (Fig. 4E). Furthermore, transfection of miR-18a-3p inhibitor into both IHPEC-II cells and hPSC-derived AEC2-like cells resulted in a significant upregulation of SFTPC mRNA levels (Fig. 4F). miR-18a-3p targeted SFTPC. A The binding site of miR-18a-3p with SFTPC. B C Dual-luciferase reporter assay results indicate that miR-18a-3p inhibitor (anti18a-3p) increased the fluorescence intensity of wild-type SFTPC (WT-SFTPC), but had no effect on the fluorescence intensity of mutant SFTPC (MUT-SFTPC). D Compared to human pluripotent stem cells (hPSCs), the expression level of SFTPC mRNA was elevated in IHPEC-Ⅱ cells; E Compared to hPSCs, the expression level of miR-18a-3p was increased in AEC2-like cells. F Transfection of miR-18a-3p inhibitor in IHPEC-Ⅱ cells and AEC2-like cells increased the expression level of SFTPC mRNA Discussion Previous research has demonstrated that miRNAs regulate key genes involved in lung development, cell differentiation, surfactant synthesis and secretion, as well as lung disease [15, 23]. In this study, we investigated the expression and cell functional role of miR-18a-3p in the context of NRDS, aiming to elucidate its potential as a biomarker and its functional implications in alveolar type II epithelial cells. This investigation revealed elevated miR-18a-3p expression in NRDS, suggesting its potential utility as a novel diagnostic biomarker for this disease. Furthermore, functional analyses demonstrated that miR-18a-3p exerted inhibitory effects on both cell viability and SPC secretion in alveolar epithelial type II cells. Mechanistically, these effects were mediated, at least in part, through targeting and downregulating the expression of SFTPC, the gene encoding SPC. In collapsed lungs of cloned bovine neonates, miR-18a-3p has been identified as an upregulated miRNA by next-generation sequencing and qRT-PCR [24]. Here, we found that miR-18a-3p was upregulated in NRDS serum, as well as in amniotic fluid. The elevated expression of miR-18a-3p in serum samples from neonates with NRDS, demonstrating an AUC of 0.86 in ROC analysis, suggests a potential biomarker role for this microRNA in NRDS diagnosis. In parallel, the correlation between increased miR-18a-3p levels in amniotic fluid and serum reinforces its potential as a fetal development marker, reflecting the health of the fetal pulmonary system. This observation corresponds with the hypothesis that miR-18a-3p might serve as an indicator of fetal lung maturity [25]. These findings suggest that miR-18a-3p could serve as a potential biomarker for NRDS. Genetic disorders that impair the production or function of surfactant protein can lead to NRDS or even severe respiratory failure in infants [26]. Dysregulation of SFTPC, in particular, typically results in a toxic gain-of-function phenotype, marked by the disruption of SPC processing and trafficking within alveolar type II epithelial cells [26]. For instance, miR-18a-3p has been reported to be associated with lung development and surfactant homeostasis [24], thus providing a plausible link to NRDS pathogenesis. Here, the observed increase in cell proliferation in alveolar epithelial type II cells following the transfection with miR-18a-3p inhibitors indicates a regulatory role for this miRNA in cellular growth dynamics. The significant increase in SPC secretion following inhibition of miR-18a-3p further elucidates its potential regulatory pathway in lung surfactant dynamics, thereby affecting NRDS progression. This observation is corroborated by previous findings that link miR-18a-3p with the regulation of surfactant homeostasis [24]. Dual-luciferase reporter assays demonstrated that miR-18a-3p inhibits the expression of wild-type SFTPC but not its mutated counterpart, underscoring the specificity of this regulatory mechanism. This specificity aligns with previous research indicating that miR-18a-3p directly interacts with the 3’ UTR of target HuR, leading to its downregulation [27]. The limitations of this study are twofold. Firstly, the sample size was relatively small, consisting of only 35 NRDS cases and 35 healthy controls. This limited data pool may not adequately represent the diverse population affected by NRDS, potentially influencing the generalizability of our findings. Additionally, the study lacked long-term clinical follow-up data, which is crucial for understanding the temporal dynamics of miR-18a-3p’s role throughout various stages of NRDS. Consequently, this absence limits our ability to draw comprehensive conclusions regarding the biomarker’s efficacy and relevance in clinical practice. Furthermore, no in vivo experiments were conducted to validate the functional role of miR-18a-3p, leaving the mechanistic insights derived from clinical samples without supporting evidence from animal models or physiological systems. Conclusion In summary, miR-18a-3p was highly expressed in patients with neonatal NRDS, showing potential as a diagnostic biomarker for NRDS. MiR-18a-3p can inhibit cell viability and SPC secretion of alveolar epithelial type II cells, partly through SFTPC. Acknowledgements Not Applicable. Authors’ contributions YJ S conceived and designed the experiments. Y J and H Y performed the experiments. YJ S, Y J and H Y contributed sample collection and statistical analysis. YJ S, Y J and H Y wrote the manuscript. All authors revised it critically for important intellectual content. All authors read and approved the final manuscript. Funding No funding was received to assist with the preparation of this work. Data availability Data can be shared upon reasonable request by the corresponding author. Declarations Ethics approval and consent to participate The study protocol was approved by The Ethics Committee of Nantong First People’s Hospital and followed the principles outlined in the Declaration of Helsinki. Written informed consent was obtained from all parents or guardians. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Data can be shared upon reasonable request by the corresponding author.